Cure8 research brief
The study identifies a botanical extract that reduced colitis severity in mice and pinpoints the PI3K/Akt/FOXO3A pathway as a possible mechanism — a potential starting point for new therapeutic research relevant to ulcerative colitis.
Researchers, clinicians interested in IBD mechanisms and preclinical therapeutics, and adult patients following research on novel UC treatments.
The paper describes controlled experiments in mice (DSS colitis) showing dose-dependent benefits of RFC on disease activity, colon damage, oxidative stress markers, and inflammatory cytokines.
Mechanistic data (network pharmacology, qPCR, Western blot) link RFC’s effects to inhibition of PI3K/Akt signaling and upregulation of FOXO3A; a PI3K agonist (740Y-P) reversed RFC’s benefits, supporting pathway involvement. This is preclinical research in animals and does not demonstrate safety or efficacy in people with UC.
More research — including pharmacology, dosing, safety, and human trials — would be needed before clinical use could be considered.
Preclinical animal study (DSS-induced colitis) reported in a peer-reviewed journal abstract; findings are exploratory and not evidence that RFC is safe or effective in humans.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: General Program of Jiangsu Traditional Chinese Medicine Science and Technology Development Plan, award MS2024091; General Program of Natural Science Foundation of Nanjing University of Chinese Medicine, award XZR2024231; award XZR2024231; Open Project of the Coordination Service Platform for Biobanks of Major Diseases, Jiangsu Provincial Department of Science and Technology, award TC2023B012; Nantong Traditional Chinese Medicine Medical Alliance Research Project, award TZYK202307; award TZYK202307
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.
The study identifies a bile acid, TUDCA, that reduced colitis severity and improved gut-barrier and antioxidant pathways in mice, pointing to a potential new therapeutic approach for intestinal inflammation. This is...
The study suggests a novel plant-derived nanoparticle approach reduced inflammation and repaired barrier function in a mouse model of colitis and changed the gut microbiome — a potential early-stage route for new IBD...
